Oral hedgehog-pathway inhibitors for basal-cell carcinoma

New England Journal of Medicine

Volumn 366, Issue 23, 2012, Pages 2225-2226

  Lear, John T ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VISMODEGIB;

ALOPECIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER RECURRENCE; CAUSAL ATTRIBUTION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LIGHT EXPOSURE; MUSCLE SPASM; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TASTE DISORDER; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; WEIGHT REDUCTION;

EID: 84861857695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1202170     Document Type: Editorial

References (7)

1. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010;375:673-85.
2. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-7.
3. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998;110:885-8. (Pubitemid 28237693)
4. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
5. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366:2171-9.
6. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8.
7. Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326:572-4.